Rigel Pharma (RIGL) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- Goldman data shows hedge funds cut leverage at fastest pace since March
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $50.53 --0%
EPS Growth %: -34.9%
Financial Fact:
Interest income: 110K
Today's EPS Names:
INM, TRI, CRVL, More
EPS Growth %: -34.9%
Financial Fact:
Interest income: 110K
Today's EPS Names:
INM, TRI, CRVL, More
Join SI Premium – FREE
Rigel Pharma (NASDAQ: RIGL) reported Q2 EPS of ($0.06), $0.04 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $36.84 million versus the consensus estimate of $33.7 million.
For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Shopify tanks 19% premarket as Q3 GMV, subscription revenue miss estimates
- The Marzetti Company (MZTI) Misses Q3 EPS by 23c
- Meta Platforms Kicks Off Five-part Us Dollar Bond Offering - Bloomberg
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
